Lack of somatic mutations in the catalytic domains of CREBBP and EP300 genes implies a role for histone deacetylase inhibition in myeloproliferative neoplasms

C.L. Andersen; K. Grønbæk; H. Hasselbalch

doi:10.1016/j.leukres.2011.11.018

Lack of somatic mutations in the catalytic domains of CREBBP and EP300 genes implies a role for histone deacetylase inhibition in myeloproliferative neoplasms

C.L. Andersen, K. Grønbæk, H. Hasselbalch

4 Citations (Scopus)

Abstract

Somatic mutations of the two genes coding for the histone acetyltransferase genes, CREEBP and EP300 have been identified as a pathogenetic mechanism shared by common forms of B-cell non-Hodgkinós lymphomas. A screening for somatic mutations in CREEBP and EP300 genes in patients with myeloproliferative neoplasms (MPNs) has not previously been performed. DNA was purified from diagnostic samples of 56 MPN patients. We designed a mutation screening assay based on denaturing gradient gel electrophoresis and direct sequencing. Our results suggest that CREBBP and EP300 mutations are not major pathogenetic mechanisms of MPNs. The rationale for using HDACi in these patients seems reasonable.

Original language	English
Journal	Leukemia Research
Volume	36
Issue number	4
Pages (from-to)	485-487
Number of pages	3
ISSN	0145-2126
DOIs	https://doi.org/10.1016/j.leukres.2011.11.018
Publication status	Published - 1 Apr 2012

Access to Document

10.1016/j.leukres.2011.11.018

Cite this

@article{166c459f93514c2a82270bb43d8f45f7,

title = "Lack of somatic mutations in the catalytic domains of CREBBP and EP300 genes implies a role for histone deacetylase inhibition in myeloproliferative neoplasms",

abstract = "Somatic mutations of the two genes coding for the histone acetyltransferase genes, CREEBP and EP300 have been identified as a pathogenetic mechanism shared by common forms of B-cell non-Hodgkin{\'o}s lymphomas. A screening for somatic mutations in CREEBP and EP300 genes in patients with myeloproliferative neoplasms (MPNs) has not previously been performed. DNA was purified from diagnostic samples of 56 MPN patients. We designed a mutation screening assay based on denaturing gradient gel electrophoresis and direct sequencing. Our results suggest that CREBBP and EP300 mutations are not major pathogenetic mechanisms of MPNs. The rationale for using HDACi in these patients seems reasonable.",

author = "C.L. Andersen and K. Gr{\o}nb{\ae}k and H. Hasselbalch",

year = "2012",

month = apr,

day = "1",

doi = "10.1016/j.leukres.2011.11.018",

language = "English",

volume = "36",

pages = "485--487",

journal = "Leukemia Research",

issn = "0145-2126",

publisher = "Pergamon Press",

number = "4",

}

TY - JOUR

T1 - Lack of somatic mutations in the catalytic domains of CREBBP and EP300 genes implies a role for histone deacetylase inhibition in myeloproliferative neoplasms

AU - Andersen, C.L.

AU - Grønbæk, K.

AU - Hasselbalch, H.

PY - 2012/4/1

Y1 - 2012/4/1

N2 - Somatic mutations of the two genes coding for the histone acetyltransferase genes, CREEBP and EP300 have been identified as a pathogenetic mechanism shared by common forms of B-cell non-Hodgkinós lymphomas. A screening for somatic mutations in CREEBP and EP300 genes in patients with myeloproliferative neoplasms (MPNs) has not previously been performed. DNA was purified from diagnostic samples of 56 MPN patients. We designed a mutation screening assay based on denaturing gradient gel electrophoresis and direct sequencing. Our results suggest that CREBBP and EP300 mutations are not major pathogenetic mechanisms of MPNs. The rationale for using HDACi in these patients seems reasonable.

AB - Somatic mutations of the two genes coding for the histone acetyltransferase genes, CREEBP and EP300 have been identified as a pathogenetic mechanism shared by common forms of B-cell non-Hodgkinós lymphomas. A screening for somatic mutations in CREEBP and EP300 genes in patients with myeloproliferative neoplasms (MPNs) has not previously been performed. DNA was purified from diagnostic samples of 56 MPN patients. We designed a mutation screening assay based on denaturing gradient gel electrophoresis and direct sequencing. Our results suggest that CREBBP and EP300 mutations are not major pathogenetic mechanisms of MPNs. The rationale for using HDACi in these patients seems reasonable.

UR - http://www.scopus.com/inward/record.url?scp=84857239094&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2011.11.018

DO - 10.1016/j.leukres.2011.11.018

M3 - Journal article

C2 - 22177454

AN - SCOPUS:84857239094

SN - 0145-2126

VL - 36

SP - 485

EP - 487

JO - Leukemia Research

JF - Leukemia Research

IS - 4

ER -

Lack of somatic mutations in the catalytic domains of CREBBP and EP300 genes implies a role for histone deacetylase inhibition in myeloproliferative neoplasms

Abstract

Access to Document

Other files and links

Fingerprint

Cite this